About BioAge Labs, Inc.
https://bioagelabs.comBioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.
CEO
Kristen Fortney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AH CAPITAL MANAGEMENT, L.L.C.
Shares:3.23M
Value:$74.1M
SOFINNOVA INVESTMENTS, INC.
Shares:2.29M
Value:$52.57M
CORMORANT ASSET MANAGEMENT, LP
Shares:2.14M
Value:$49.06M
Summary
Showing Top 3 of 95
About BioAge Labs, Inc.
https://bioagelabs.comBioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.05M ▼ | $25.19M ▼ | $-20.17M ▲ | -982.04% ▼ | $-0.56 ▲ | $-19.97M ▲ |
| Q2-2025 | $2.41M ▲ | $27.18M ▲ | $-21.56M ▼ | -893.99% ▼ | $-0.6 ▼ | $-21.3M ▼ |
| Q1-2025 | $1.45M ▲ | $17.9M ▼ | $-12.93M ▲ | -890.97% ▼ | $-0.36 ▲ | $-12.64M ▲ |
| Q4-2024 | $0 | $25.36M ▲ | $-21.13M ▲ | 0% | $-1.97 ▲ | $-20.76M ▲ |
| Q3-2024 | $0 | $24.75M | $-23.41M | 0% | $-6.7 | $-22.98M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $285.78M ▼ | $305.09M ▼ | $27.63M ▲ | $277.46M ▼ |
| Q2-2025 | $297.3M ▼ | $322.15M ▼ | $27.37M ▼ | $294.78M ▼ |
| Q1-2025 | $320.52M ▼ | $343.84M ▼ | $30.67M ▼ | $313.17M ▼ |
| Q4-2024 | $354.35M ▲ | $358.23M ▲ | $35.11M ▲ | $323.13M ▲ |
| Q3-2024 | $334.47M | $337.38M | $23.63M | $313.75M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.17M ▲ | $-16.04M ▲ | $12.84M ▲ | $-1.54M ▼ | $-4.76M ▲ | $-16.07M ▲ |
| Q2-2025 | $-21.56M ▼ | $-19.97M ▼ | $-15.64M ▲ | $-1.5M | $-37.16M ▲ | $-20.13M ▼ |
| Q1-2025 | $-12.93M ▲ | $-17.36M ▼ | $-77.99M ▼ | $-1.5M ▼ | $-96.86M ▼ | $-17.79M ▼ |
| Q4-2024 | $-21.13M ▲ | $-5.14M ▲ | $-26K ▲ | $24.9M ▼ | $19.88M ▼ | $-5.16M ▲ |
| Q3-2024 | $-23.41M | $-14.93M | $-305K | $190.68M | $175.39M | $-15.24M |
CEO
Kristen Fortney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AH CAPITAL MANAGEMENT, L.L.C.
Shares:3.23M
Value:$74.1M
SOFINNOVA INVESTMENTS, INC.
Shares:2.29M
Value:$52.57M
CORMORANT ASSET MANAGEMENT, LP
Shares:2.14M
Value:$49.06M
Summary
Showing Top 3 of 95